Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$78,550.00+1.87%ETH$2,329.83+2.76%GOLD$4,052.40+2.84%OIL$95.53-0.58%
Smart Investors Daily
SID Premium
RX

NASDAQ · RXST

RxSight, Inc.

Healthcare · Medical - Devices

$4.59

Down-$0.21 (-4.38%)

Updated Nov 4, 2026, 11:23 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
539.04M
P/E ratio
-16.56
Dividend yield
0.00%
52-week range
$4.40 – $13.22
Volume
1.2M
Avg. volume
777.3K

Price performance · RXST

RXST price history

1M range · 0 trading sessions · Daily adjusted prices

RXST does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RXST news

The latest Smart Investors Daily articles mentioning RXST.

Stock researchCompany · Overview

RXST research

Overview

Company profile and research snapshot.

Company profile

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
RXST recent ratings
DateFirmRatingTarget
Sep 22, 2026JefferiesHold—
Sep 22, 2026B of A SecuritiesUnderperform—
Aug 10, 2026StifelHold—
Aug 6, 2026UBSNeutral—
Jul 7, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight’s common stock to the same employees in

Yahoo · Oct 20, 2026

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8782462. The call will a

Yahoo · Oct 19, 2026

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy. The appointments strengthen RxSight’s commercial leadership team and support the company’s efforts to enhance commercial execution and accelerate adoption of RxSight’s Light Adjustable Lens™ (LAL™) technology. “Over the past several months, we have prioritize

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By